Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what recent assessment her Department has made of the adequacy of supplies of Elvanse 30mg ADHD medication.

Disruptions to the supply of medicines used for the management of attention deficit hyperactivity disorder (ADHD), including lisdexamfetamine (Elvanse), have been primarily driven by issues which have resulted in capacity constraints at key manufacturing sites. The Department has been working closely with the respective manufacturers and some issues have now been resolved. Regarding Elvanse 30 milligram capsules, resupplies of this specific product are expected in late January 2024. However, we know that there continue to be disruptions to the supply of some other Elvanse products, which should resolve by April 2024.